Stryker Co. (SYK) is LaFleur & Godfrey LLC’s 5th Largest Position

LaFleur & Godfrey LLC lowered its stake in shares of Stryker Co. (NYSE:SYK) by 8.1% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 79,504 shares of the medical technology company’s stock after selling 6,970 shares during the quarter. Stryker comprises 4.1% of LaFleur & Godfrey LLC’s portfolio, making the stock its 5th largest holding. LaFleur & Godfrey LLC’s holdings in Stryker were worth $15,704,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently made changes to their positions in SYK. Accredited Investors Inc. boosted its position in shares of Stryker by 15.3% in the first quarter. Accredited Investors Inc. now owns 1,695 shares of the medical technology company’s stock valued at $335,000 after acquiring an additional 225 shares during the period. Bank of Stockton boosted its position in shares of Stryker by 1.1% in the first quarter. Bank of Stockton now owns 6,656 shares of the medical technology company’s stock valued at $1,313,000 after acquiring an additional 70 shares during the period. Kistler Tiffany Companies LLC boosted its position in shares of Stryker by 167.0% in the first quarter. Kistler Tiffany Companies LLC now owns 275 shares of the medical technology company’s stock valued at $54,000 after acquiring an additional 172 shares during the period. Cohen Klingenstein LLC bought a new stake in shares of Stryker in the first quarter valued at approximately $265,000. Finally, Argus Investors Counsel Inc. boosted its position in shares of Stryker by 2.0% in the first quarter. Argus Investors Counsel Inc. now owns 24,934 shares of the medical technology company’s stock valued at $4,925,000 after acquiring an additional 489 shares during the period. 74.61% of the stock is owned by hedge funds and other institutional investors.

In other Stryker news, VP M Kathryn Fink sold 180 shares of the stock in a transaction on Monday, February 4th. The stock was sold at an average price of $176.77, for a total transaction of $31,818.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Michael Damon Hutchinson sold 15,995 shares of the firm’s stock in a transaction on Friday, February 8th. The shares were sold at an average price of $180.49, for a total value of $2,886,937.55. The disclosure for this sale can be found here. Insiders have sold 130,455 shares of company stock valued at $24,723,292 over the last quarter. Corporate insiders own 7.20% of the company’s stock.

Several equities research analysts have recently weighed in on the company. Wells Fargo & Co increased their price objective on Stryker from $214.00 to $219.00 and gave the company an “outperform” rating in a research report on Monday, April 1st. Zacks Investment Research cut Stryker from a “buy” rating to a “hold” rating in a research report on Friday, April 12th. BTIG Research increased their price objective on Stryker to $211.00 and gave the company a “buy” rating in a research report on Monday, March 18th. Barclays increased their price objective on Stryker from $203.00 to $211.00 and gave the company an “overweight” rating in a research report on Monday. Finally, JPMorgan Chase & Co. increased their price objective on Stryker from $200.00 to $215.00 and gave the company an “overweight” rating in a research report on Tuesday, March 19th. Nine research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Stryker presently has a consensus rating of “Buy” and a consensus target price of $192.13.

Shares of NYSE SYK opened at $180.24 on Thursday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.02 and a quick ratio of 1.41. The firm has a market capitalization of $72.17 billion, a P/E ratio of 24.66, a PEG ratio of 2.38 and a beta of 0.88. Stryker Co. has a one year low of $144.75 and a one year high of $199.85.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 29th. The medical technology company reported $2.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.15 by $0.03. Stryker had a return on equity of 27.60% and a net margin of 26.12%. The firm had revenue of $3.80 billion during the quarter, compared to analyst estimates of $3.73 billion. Equities analysts anticipate that Stryker Co. will post 8.13 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be paid a dividend of $0.52 per share. The ex-dividend date is Thursday, March 28th. This represents a $2.08 annualized dividend and a yield of 1.15%. Stryker’s dividend payout ratio is currently 28.45%.

ILLEGAL ACTIVITY NOTICE: “Stryker Co. (SYK) is LaFleur & Godfrey LLC’s 5th Largest Position” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2019/04/18/stryker-co-syk-is-lafleur-godfrey-llcs-5th-largest-position.html.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Story: Trading Ex-Dividend Strategy

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.